| abstract |
Use of galectin-2 or of a nucleic acid coding for galectin-2 or of its complementary strand, or of a nucleic acid hybridizing to such coding nucleic acid or its complementary strand, for the manufacture of a medicament for the treatment or prevention of a patient having a disease with impaired apoptosis of T-cells, macrophages and/or antigen-presenting cells, or for the manufacture of a medicament for the treatment or prevention of organ rejection in a patient having undergone organ transplantation, in particular solid organ transplantation. |